Silence Therapeutics plc

Silence Therapeutics announced positive topline results from its Phase 2 SANRECO trial of divesiran for polycythemia vera (PV). The trial met its primary endpoint, showing a significantly higher proportion of clinical responders (88%) in the divesiran group compared to placebo (19%). Both Q6W and Q12W dosing regimens demonstrated substantial efficacy and the drug was well tolerated with no new safety concerns. The company plans to initiate a Phase 3 trial in the first half of 2027.

Silence Therapeutics reported a net loss of $12.3 million for Q2 2026 and $27.2 million for the first half of 2026. The company's cash and cash equivalents stood at $72.1 million as of June 30, 2026, which it believes is sufficient to fund operations into 2028. Operating loss and net cash used in operations decreased significantly compared to the prior year, despite zero revenue in Q2 2026.

Silence Therapeutics reported its second quarter 2026 financial and business results, showing a significant reduction in net loss to $12.3 million, down from $27.4 million in the prior year. R&D expenses also decreased to $9.1 million. The company announced the completion of patient dosing in the Phase 2 SANRECO trial for divesiran and presented positive Phase 1 results for SLN312. Additionally, two preclinical programs, SLN365 and SLN098, are on track for IND filings in 2027.

Silence Therapeutics plc has provided details regarding the separation agreement with Craig Tooman, whose employment ended on December 14, 2025. The agreement, entered into on July 10, 2026, outlines various compensatory arrangements. These include salary continuation for 12 months, a lump sum severance payment, a 2025 bonus payment, and reimbursements for legal and healthcare expenses. The agreement also details terms for continued vesting and extended exercise periods for stock options.

Silence Therapeutics plc announced the issuance of an updated corporate presentation, reflecting recent business developments and pipeline advancements. The presentation highlights significant progress across its siRNA therapeutic programs, including anticipated Phase 2 topline results for Divesiran in Polycythemia Vera in Q3 2026. Additionally, the company is set to regain global rights to SLN312 for dyslipidemia and is advancing preclinical programs for SLN365 and SLN098 with potential IND filings targeted for 2027.

Silence Therapeutics plc presented follow-up and quality-of-life data from its Phase 1 SANRECO study of divesiran, a siRNA therapy for polycythemia vera (PV), at the EHA 2026 Annual Congress. The data demonstrated durable efficacy, showing substantial and persistent reductions in phlebotomy use, as well as potential improvements in PV symptoms and patient quality-of-life. Divesiran was well tolerated with no serious adverse events. The company anticipates topline results from its ongoing Phase 2 SANRECO study in August 2026, which is evaluating less frequent dosing regimens.

Silence Therapeutics plc has entered into a new Open Market Sale AgreementSM with Jefferies LLC, allowing the company to offer and sell American Depositary Shares (ADSs) from time to time. This new agreement replaces and terminates a prior sales agreement from October 2021. Additionally, the company updated its disclosures, stating that following further tax analysis, it now believes it was not classified as a Passive Foreign Investment Company (PFIC) for its taxable year ended December 31, 2025.

Silence Therapeutics plc reported a significant reduction in net loss for the first quarter of 2026, narrowing to $(14.96) million from $(28.53) million in the prior year. Revenue also saw an increase to $0.42 million. Despite these improvements, the company continues to incur operating losses and will require additional funding for its clinical development activities, although it believes current cash is sufficient into 2028.

Silence Therapeutics plc reported its financial results for the first quarter ended March 31, 2026, with a net loss of $15.0 million, a significant improvement from $28.5 million in the prior year, primarily due to lower R&D expenses. The company also provided an update on recent business achievements, including the SANRECO Phase 2 trial of divesiran for polycythemia vera remaining on track for topline results in August 2026. Additionally, an abstract for the SLN312 Phase 1 study for dyslipidemia was accepted for a late-breaking oral presentation.

Silence Therapeutics plc announced its 2026 Annual General Meeting (AGM) will be held on Tuesday, June 16, 2026, as a hybrid meeting in Hoboken, NJ, and electronically. Shareholders will vote on nine ordinary resolutions, including the re-appointment of two directors, the ratification and re-appointment of PricewaterhouseCoopers LLP as auditors, and the approval of the 2025 U.K. annual accounts and directors' remuneration report. The board recommends voting for all proposed resolutions.